Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the efficacy and safety of a combined oral contraceptive of estradiol valerate and dienogest in healthy female subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| EV/DNG (Qlaira, BAY86-5027) | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EV/DNG (Qlaira, BAY86-5027) | Drug | Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of unintended pregnancies | Up to Cycle 13 (1 Cycle = 28 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of expected bleeding days | Up to Cycle 13 (1 Cycle = 28 days) | |
| Number of unexpected bleeding days | Up to Cycle 13 (1 Cycle = 28 days) | |
| Number of expected bleeding episodes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Guangzhou | Guangdong | 510120 | China | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29922096 | Derived | Yu Q, Huang Z, Ren M, Chang Q, Zhang Z, Parke S. Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study. Int J Womens Health. 2018 Jun 7;10:257-266. doi: 10.2147/IJWH.S157056. eCollection 2018. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Up to Cycle 13 (1 Cycle = 28 days) |
| Number of unexpected bleeding episodes | Up to Cycle 13 (1 Cycle = 28 days) |
| Number of participants with Adverse Events as a Measure of Safety and Tolerability | Up to Cycle 13 (1 Cycle = 28 days) |
| Guangzhou |
| Guangdong |
| 510405 |
| China |
| Shijiazhuang | Hebei | 050051 | China |
| Wuhan | Hubei | 430030 | China |
| Wuhan | Hubei | 430032 | China |
| Changsha | Hunan | 410013 | China |
| Hengyang | Hunan | 421001 | China |
| Nanjing | Jiangsu | 210009 | China |
| Dalian | Liaoning | 116011 | China |
| Shenyang | Liaoning | 110004 | China |
| Jinan | Shandong | 250012 | China |
| Chengdu | Sichuan | 610041 | China |
| Wenzhou | Zhejiang | 325027 | China |
| Beijing | 100044 | China |
| Beijing | 100730 | China |
| Chongqing | 400016 | China |
| Chongqing | 400038 | China |
| Chongqing | 400042 | China |
| Shanghai | 200025 | China |
| Shanghai | 200030 | China |
| Shanghai | 200127 | China |
| Shanghai | 2100129 | China |
| Tianjin | 300211 | China |
| Hong Kong | Hong Kong |
| Pune | Maharashtra | 411001 | India |
| Chandigarh | India |
| Karnāl | 132001 | India |
| New Delhi | 110 029 | India |
| Pune | 411004 | India |
| Secunderabad | 500003 | India |
| Taipei | Taipei | 116 | Taiwan |
| Kaohsiung City | 80756 | Taiwan |
| Taichung | 40705 | Taiwan |
| Taipei | 100 | Taiwan |
| Taipei | 11217 | Taiwan |
| Taoyuan | 333 | Taiwan |
| Bangkok | Thailand | 10330 | Thailand |
| Bangkok | 10700 | Thailand |
| Chiang Mai | 50200 | Thailand |